Discovery facts: Marijuana in the treatment of Alzheimer’s disease.
Back in early 2008, several reports appeared in scientific publications describing various possible physiological mechanisms by which cannabinoids can be used in the treatment of Alzheimer’s disease symptoms. The public attention was attracted by the work of the laboratory Molecular Pharmaceutics , but unfortunately, none of these studies could provide the medical community with convincing evidence of the effectiveness of cannabis treatment of the disease.
By 2014, a group of scientists made a scientific breakthrough in this field of research, documenting the ability of cannabinoids to alleviate the symptoms of the disease and prevent its progression. This work was published on the pages of a scientific journal dedicated to the treatment of Alzheimer’s disease.
In particular, the authors of the work, a professor of neurology at the University of South Florida, named Tyunhai Ho, told reporters: “Low doses of THC (one of the main psychoactive components of the cannabis plant) have a noticeable therapeutic effect on patients. This compound is able to come into contact with proteins from the Beta-Amyloid group, the main causative agents of Alzheimer’s disease symptoms, destroying their accumulations in the area of the cerebral cortex. By reducing the dies of the Beta-Amyloid Cluster, THC weakens the progression and manifestation of the disease. ”
Ram Mukunda, President of Global Venture Company India Globalization Capital Inc., which deals with the financing of research in the field of hemp medicine, also spoke about the discovery. “Alzheimer’s disease is manifested when Beta-Amyloid is excessively accumulated around neurons in the cerebral cortex. These dense protein dies are able to suppress and completely block the signals of neurons, thereby impairing their communication, and therefore the cognitive and emotional functions of the brain. Naturally, the fact that this disease, which is not amenable to treatment with pharmaceutical preparations, can be treated with the help of the component of the world widespread cannabis plant is a worthy occasion for a holiday in the medical community, ”says Mr. Mukunda.
Future research plans:
Despite the fact that the work of 2014 established the ability of cannabinoids to eliminate the cause of the disease, its authors warned the public about two points that they had not studied in detail. In particular, Professor Ho warns doctors that science is still unknown how TGC’s can be safe and effective for all Alzheimer’s patients. Since the experiment for the work was carried out without the support of a university or state government, with a rather narrow sample of volunteers, its results are not sufficient for formal recognition of the therapeutic efficacy of THC.
Anyway, with the beginning of the current wave of legalization in Europe and America, the number of published works on various medical properties of marijuana has increased markedly. Most of the tests noted the absence of serious side effects from THC in a wide variety of patients, even during its long-term consumption . Also, one group of scientists, in the course of private experiments, was already able to align a therapeutically effective dose of THC for the treatment of Alzheimer’s symptoms .
The effectiveness of hemp therapy for Alzheimer’s disease is also confirmed by the results of two independent experiments conducted in the past and current years. General information about the results of therapy is given in the issue of the journal Nature.
Shortly after confirming the ability of THC compounds to destroy Beta Amyloids and prevent them from accumulating on neurons, the University of South Florida registered a patent for a potential Alzheimer’s disease drug based on THC.
After several months of negotiations, India Globalization Capital was able to buy a patent from the University, promising to provide a potential drug to the world.
“We plan to conduct a series of clinical trials of THC in Alzheimer’s therapy,” Mr. Mukunda told reporters. “Different tests of a substance can be carried out in different countries of the world, after which, having achieved recognition of the effectiveness of THC, we can begin to distribute it to all in need.”
At the moment, company representatives are looking for outside investors who are willing to invest in the testing and subsequent production of the medicine.
In addition to India Globalization Capital, GW Pharmaceuticals PLC, Zynerba Pharmaceuticals Inc. and Insys Therapeutics Inc. are currently involved in the development of hemp drugs. Despite the fairly close competition in the market, Mukunda emphasizes the main production of his company. “Unlike other participants, we work not only with isolated THC, but also with all the components of a natural cannabis plant,” he says.